Last reviewed · How we verify
IBR854
At a glance
| Generic name | IBR854 |
|---|---|
| Sponsor | Imbioray (Hangzhou) Biomedicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma (PHASE2)
- Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |